NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
IntroductionParkinson's disease (PD) lacks reliable non-invasive diagnostic biomarkers. Urine is a promising biofluid for biomarker discovery, but the profound influence of shared environment and lifestyle represents a major confounder.MethodsTo rigorously address this, we designed a pilot study using a unique matched-pair cohort: PD patients together with their healthy spouses. Untargeted LC-MS metabolomics was performed on urine samples from 15 carefully matched pairs. Differential features were identified using VIP > 1.0 and p ResultsA preliminary five-metabolite panel (Cyanuric acid, Benzeneacetonitrile, 3-Formylsalicylic Acid, dADP, and ent-cassa-12,15-dien-2beta-ol) was defined. Despite the inherently small sample size of this niche cohort, the panel demonstrated promising internal discriminative performance (AUC > 0.95).DiscussionWe emphasize that these results are exploratory. The primary contribution of this pilot study is not a validated diagnostic tool, but the demonstration of a carefully controlled design to isolate PD-specific metabolic signatures and the proposal of specific candidate biomarkers. This work establishes a critical proof-of-concept and prioritizes targets for essential future validation in larger, independent cohorts.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.